CELSR3 Antibody

Code CSB-PA981972
Size US$297
Order now
Image
  • Immunohistochemistry analysis of paraffin-embedded human brain tissue using CELSR3 antibody.
  • Immunofluorescence analysis of HepG2 cells, using CELSR3 antibody.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) CELSR3 Polyclonal antibody
Uniprot No.
Target Names
CELSR3
Alternative Names
Anchor protein antibody; Cadherin EGF LAG seven-pass G-type receptor 3 antibody; Cadherin family member 11 antibody; CDHF11 antibody; CELR3_HUMAN antibody; Celsr3 antibody; EGF like domain multiple 1 antibody; EGF-like protein 1 antibody; EGFL1 antibody; Epidermal growth factor-like protein 1 antibody; Flamingo antibody; Flamingo homolog 1 antibody; FMI1 antibody; hFmi1 antibody; MEGF2 antibody; Multiple EGF-like domains protein 2 antibody; Multiple epidermal growth factor-like domains protein 2 antibody; RESDA1 antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Synthesized peptide derived from internal of Human CELSR3.
Immunogen Species
Homo sapiens (Human)
Clonality
Polyclonal
Purification Method
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration
It differs from different batches. Please contact us to confirm it.
Form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Tested Applications
ELISA,IHC,IF
Recommended Dilution
Application Recommended Dilution
IHC 1:50-1:100
IF 1:100-1:500
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Receptor that may have an important role in cell/cell signaling during nervous system formation.
Gene References into Functions
  1. Study identifies four likely Tourette disorder risk genes with multiple de novo damaging variants in unrelated probands: WWC1 (WW and C2 domain containing 1), CELSR3 (Cadherin EGF LAG seven-pass G-type receptor 3), NIPBL (Nipped-B-like), and FN1 (fibronectin 1). PMID: 28472652
  2. marked reduction in the prominence of TUJ1 bundles in number, thickness, and length. Our results showed that deregulation of the planar cell polarity genes CELSR3 and FZD3 might disrupt the enteric innervation pattern PMID: 27619161
  3. A moderate positive correlation between CELSR3 and patient age was also evident. PMID: 26838213
  4. seven-transmembrane domain receptors Celsr3 and Fzd3, in particular, control the development of most longitudinal tracts in the central nervous system. [Review] PMID: 25813877
  5. CELSR3 promoter hypermethylation is associated with oral squamous cell carcinoma. PMID: 25374236
  6. CELSR3 was found to be selectively up-regulated in tumor stellate cells. PMID: 20416094
  7. CELSR3 is one of the core PCP signaling molecules. PMID: 16273260

Show More

Hide All

Subcellular Location
Cell membrane; Multi-pass membrane protein.
Protein Families
G-protein coupled receptor 2 family, LN-TM7 subfamily
Database Links

HGNC: 3230

OMIM: 604264

KEGG: hsa:1951

STRING: 9606.ENSP00000164024

UniGene: Hs.631926

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*